CSL Behring has advised HFA and NHF of a printing misalignment on the label of its Humate P product for von Willebrand disease. You can read CSL Behring’s statement, and see images of the product box,Â below.
While the current Humate P notification is prompted by a printing error on the outside of the box, NHF and HFA have nonetheless opted to publish this notice to the community. We understand that the recent spate of product-related announcements may have been unsettling for some members of the bleeding disorders community but, for the present, the national patient organizations are choosing to post all public notices of FDA- and safety-related product announcements. If you would like to share your thoughts on NHF’s and HFA’s communication to the bleeding disorders community regarding product safety, we welcome your comments at The Patient Voice: Products Safety Issues.
Please note that NHF and HFA do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. Please consult your physician before use of any treatments.
Word From Washington